Literature DB >> 19215987

Patterns of major depression and drug-related problems amongst heroin users across 36 months.

Shane Darke1, Katherine Mills, Maree Teesson, Joanne Ross, Anna Williamson, Alys Havard.   

Abstract

The study aimed to determine patterns of major depression (MD) across 36 months, and the relationship to outcomes for the treatment of heroin dependence. As part of a longitudinal cohort study, 429 heroin users were interviewed at 36 month follow-up. MD declined from 23.8% at baseline to 8.2% at 36 months. Females were more likely to have MD at both baseline (31.1 vs. 19.8) and 36 months (11.9 vs. 6.1%). Those with MD at baseline were significantly more likely to be diagnosed with MD at a follow-up interview (40.2 vs. 15.9%) and at 36 months (14.7 vs. 6.1%). Antidepressant use did not decrease across 36 months amongst either gender. Baseline MD was not related to treatment exposure across 36 months. There were large and significant declines in drug use and drug-related problems, and improvements in physical health with no group differences evident at 36 months. Despite improvements in global mental health, at both baseline and 36 months those with MD at baseline had significantly lower SF12 mental health scores. It was concluded that, with the exception of depression, the prognosis of depressed heroin users is not worse than that of non-depressed users.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19215987     DOI: 10.1016/j.psychres.2007.12.007

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  20 in total

1.  Prevalence of mood and substance use disorders among patients seeking primary care office-based buprenorphine/naloxone treatment.

Authors:  Jonathan D Savant; Declan T Barry; Christopher J Cutter; Michelle T Joy; An Dinh; Richard S Schottenfeld; David A Fiellin
Journal:  Drug Alcohol Depend       Date:  2012-07-06       Impact factor: 4.492

2.  Associations between subtypes of major depressive episodes and substance use disorders.

Authors:  Naomi R Marmorstein
Journal:  Psychiatry Res       Date:  2010-10-28       Impact factor: 3.222

3.  Antidepressant treatment does not improve buprenorphine retention among opioid-dependent persons.

Authors:  Michael D Stein; Debra S Herman; Malyna Kettavong; Patricia A Cioe; Peter D Friedmann; Tahir Tellioglu; Bradley J Anderson
Journal:  J Subst Abuse Treat       Date:  2010-07-03

4.  Psychiatric symptoms, quality of life, and HIV status among people using opioids in Saint Petersburg, Russia.

Authors:  Alethea Desrosiers; Elena Blokhina; Evgeny Krupitsky; Edwin Zvartau; Richard Schottenfeld; Marek Chawarski
Journal:  Drug Alcohol Depend       Date:  2017-01-23       Impact factor: 4.492

5.  Do gender differences in depression remain after controlling for early maladaptive schemas? An examination in a sample of opioid dependent treatment seeking adults.

Authors:  Ryan C Shorey; Gregory L Stuart; Scott Anderson
Journal:  Clin Psychol Psychother       Date:  2012-02-14

6.  Impaired emotional-like behavior and serotonergic function during protracted abstinence from chronic morphine.

Authors:  Celia Goeldner; Pierre-Eric Lutz; Emmanuel Darcq; Thomas Halter; Daniel Clesse; Abdel-Mouttalib Ouagazzal; Brigitte L Kieffer
Journal:  Biol Psychiatry       Date:  2010-10-14       Impact factor: 13.382

7.  Distinct mu, delta, and kappa opioid receptor mechanisms underlie low sociability and depressive-like behaviors during heroin abstinence.

Authors:  Pierre-Eric Lutz; Gulebru Ayranci; Paul Chu-Sin-Chung; Audrey Matifas; Pascale Koebel; Dominique Filliol; Katia Befort; Abdel-Mouttalib Ouagazzal; Brigitte L Kieffer
Journal:  Neuropsychopharmacology       Date:  2014-05-30       Impact factor: 7.853

8.  Mental health of heroin users with differing injection drug use histories: A non-treatment sample of Mexican American young adult men.

Authors:  Kathryn M Nowotny; Tasha Perdue; Alice Cepeda; Avelardo Valdez
Journal:  Drug Alcohol Depend       Date:  2017-10-07       Impact factor: 4.492

9.  Interim buprenorphine treatment during delays to comprehensive treatment: Changes in psychiatric symptoms.

Authors:  Joanna M Streck; Taylor A Ochalek; Gary J Badger; Stacey C Sigmon
Journal:  Exp Clin Psychopharmacol       Date:  2018-06-25       Impact factor: 3.157

10.  Mediational Pathways Among Trait Impulsivity, Heroin-use Consequences, and Current Mood State.

Authors:  Holly H Reid; Leslie H Lundahl; Jamey J Lister; Eric A Woodcock; Mark K Greenwald
Journal:  Addict Res Theory       Date:  2018-01-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.